Welcome to our dedicated page for Cybin news (Ticker: HELP), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Helus Pharma reports news on clinical-stage pharmaceutical development for novel serotonergic agonists in mental health. Recurring updates cover HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, clinical and regulatory disclosures, research collaborations, and medical or scientific leadership.
Company news also includes governance changes, executive and advisory appointments, shareholder voting matters, capital-structure disclosure, operating and financial results, and participation in healthcare and life-sciences forums tied to the company's depression and anxiety pipeline.
Helus Pharma (Nasdaq: HELP) announced its U.S. listing migration to the Nasdaq Global Market and ongoing trading on Cboe Canada under HELP, and said it will operate under the business name Helus Pharma. The company highlighted two lead programs: HLP003, a Phase 3 NSA with Breakthrough Therapy Designation for adjunctive major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder with a topline readout expected in Q1 2026. The company cited >350 filed patents (100+ granted) and said commercialization preparations for HLP003 are underway, subject to receipt of necessary approvals.